Cost–Utility Analysis of Pharmacogenetic Testing Based on CYP2C19 or CYP2D6 in Major Depressive Disorder: Assessing the Drivers of Different Cost-Effectiveness Levels from an Italian Societal Perspective
Andrea Carta, Maria Del Zompo, Anna Meloni, Francesco Mola, Pasquale Paribello, Federica Pinna, Marco Pinna, Claudia Pisanu, Mirko Manchia, Alessio Squassina, Bernardo Carpiniello, Claudio Conversano
Dive into the research topics of 'Cost–Utility Analysis of Pharmacogenetic Testing Based on CYP2C19 or CYP2D6 in Major Depressive Disorder: Assessing the Drivers of Different Cost-Effectiveness Levels from an Italian Societal Perspective'. Together they form a unique fingerprint.